Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Khan Website

Javed Khan, M.D.

Selected Publications

1)  Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Cancer Discov. 4: 216-31, 2014.
[Journal]
2)  Metaferia B, Wei JS, Song YK, Evangelista J, Aschenbach K, Johansson P, Wen X, Chen Q, Lee A, Hempel H, Gheeya JS, Getty S, Gomez R, Khan J.
Development of peptide nucleic acid probes for detection of the HER2 oncogene.
PLoS ONE. 8: e58870, 2013.
[Journal]
3)  Abdul-Karim R, Berkman BE, Wendler D, Rid A, Khan J, Badgett T, Hull SC.
Disclosure of incidental findings from next-generation sequencing in pediatric genomic research.
Pediatrics. 131: 564-71, 2013.
[Journal]
4)  Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorg. Med. Chem. Lett. 23: 4398-403, 2013.
[Journal]
5)  Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ.
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Oncogene. 32: 5429-38, 2013.
[Journal]
6)  Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.
Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma.
PLoS ONE. 8: e77731, 2013.
[Journal]
7)  Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.
Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534).
PLoS ONE. 8: e76551, 2013.
[Journal]
8)  Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM.
The genetic landscape of high-risk neuroblastoma.
Nat. Genet. 45: 279-84, 2013.
[Journal]
9)  Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, Martins MS, Bunney TD, Santich BH, Moir S, Kuhns DB, Long Priel DA, Ombrello A, Stone D, Ombrello MJ, Khan J, Milner JD, Kastner DL, Aksentijevich I.
A hypermorphic missense mutation in PLCG2, encoding phospholipase C?2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.
Am. J. Hum. Genet. 91: 713-20, 2012.
[Journal]
10)  Ren L, Hong SH, Chen QR, Briggs J, Cassavaugh J, Srinivasan S, Lizardo MM, Mendoza A, Xia AY, Avadhani N, Khan J, Khanna C.
Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.
Cancer Res. 72: 1001-12, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/7/2014.